Cell line · CVCL_0543
Papers34
1 to 20 of 34
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Vitamin D decreases tumor cell growth and invasiveness in primary malignant bone tumors in vitro. | J Bone Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MITF maintains genome stability in nonmelanocyte lineages. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mitochondrial dysfunction activates ADAMTS-5 expression via mt-dsRNA-PKR-Spi-1 axis in osteoarthritic chondrocytes. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Drug Screening of Sarcoma Cells: Finding Shared Sensitivities. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LARS promotes osteosarcoma proliferation through leucine-dependent PRIM2 translation and DNA replication activation. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Exploring adenosine analogs for chondrosarcoma therapy: In vitro and in vivo insights. | Mol Ther Nucleic Acids | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pharmacologic inhibition of CSF-1R suppresses intrinsic tumor cell growth in osteosarcoma with CSF-1R overexpression. | J Transl Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Genetic transcriptional regulation profiling of cartilage reveals pathogenesis of osteoarthritis. | EBioMedicine | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Protein Phosphatase 1 Regulatory Subunit 3C integrates cholesterol metabolism and isocitrate dehydrogenase in chondrocytes and neoplasia. | Proc Natl Acad Sci U S A | 2025 | Its Methods give the RRID and name the line | PubMed | |
| NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion. | Mol Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Decoupling NAD+ metabolic dependency in chondrosarcoma by targeting the SIRT1-HIF-2α axis. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| YBX1-interacting small RNAs and RUNX2 can be blocked in primary bone cancer using CADD522. | J Bone Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy. | Cells | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Hsa_circ_0097271 Knockdown Attenuates Osteosarcoma Progression via Regulating miR-640/MCAM Pathway. | Dis Markers | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Shikonin derivatives cause apoptosis and cell cycle arrest in human chondrosarcoma cells via death receptors and MAPK regulation. | BMC Cancer | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Activation of efficient DNA repair mechanisms after photon and proton irradiation of human chondrosarcoma cells. | Sci Rep | 2021 | Its Methods give the RRID and name the line | PubMed | |
| The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1+ macrophages as a promising therapeutic target. | J Bone Oncol | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Translational regulation contributes to the secretory response of chondrocytic cells following exposure to interleukin-1β. | J Biol Chem | 2019 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0543/papers